Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Patients with Recent Acute Coronary Syndrome
NCT01663402Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2012
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 57
01
Overview
A Phase 3 trial of alirocumab in acute coronary syndrome (ACS), hypercholesterolemia, sponsored by Sanofi. Started Oct 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
acute coronary syndrome (ACS)hypercholesterolemia
Beyond the preview
Go deeper on NCT01663402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663402.